Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting ...Middle East

MARLBOROUGH, Mass., June 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented a...

Hence then, the article about phio pharmaceuticals presents study outline of its first clinical trial with ph 762 for advanced melanoma at the 2022 asco annual meeting was published today ( Monday 06/06/2022 - 09:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting )

Also on site :

• Katie Couric Shares Photo From Hospital Bed With Important PSA: 'Wish Me Luck'
• Russia-Ukraine war: List of key events, day 1,428
• Thrash Metal Icon Reveals Truth About Final Album of 43-Year-Old Band